 Magnetic resonance-guided high-intensity focused ultrasound MRgHIFU system for the noninvasive treatment of uterine fibroids has been developed and was approved by the US Food and Drug Administration FDA in 2004. The ultrasound waves emitted by the ultrasonic probe propagate through the skin, fat, muscle, soft tissues and converge on fibroids at focus. High energyintensity at focus causes the thermal necrosis of the fibroid tissue in several seconds. The whole process of HIFU ablation of fibroids is monitored and guided by MR thermometery. The advantage of MR-HIFU modality includes no incision, outpatient treatment and few side effects. 